Triple

T21289791
Position Surface form Disambiguated ID Type / Status
Subject Paul Schimmel E524754 entity
Predicate coFounded P104 FINISHED
Object aTyr Pharma NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: aTyr Pharma | Statement: [Paul Schimmel, coFounded, aTyr Pharma]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: aTyr Pharma
Context triple: [Paul Schimmel, coFounded, aTyr Pharma]
  • A. Array BioPharma
    Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
  • B. Acorda Therapeutics
    Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
  • C. Abellion
    Abellion is a Celtic deity, likely associated with the sun or light, venerated in the region of ancient Aquitania.
  • D. Ariad Pharmaceuticals
    Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
  • E. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: aTyr Pharma
Target entity description: aTyr Pharma is a biotherapeutics company focused on developing innovative protein-based therapies, particularly targeting rare and severe diseases.
  • A. Array BioPharma
    Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
  • B. Acorda Therapeutics
    Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
  • C. Abellion
    Abellion is a Celtic deity, likely associated with the sun or light, venerated in the region of ancient Aquitania.
  • D. Ariad Pharmaceuticals
    Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
  • E. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b5171f6c8190a5d57201ede73811 completed April 16, 2026, 10:08 a.m.
NER Named-entity recognition batch_69e736d9467881908ec5b1dec76e6f5d completed April 21, 2026, 8:35 a.m.
Created at: April 16, 2026, 4:03 p.m.